Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 295-304 , October 2001

BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling

References 

  1. Eeles RA. Screening for hereditary cancer and genetic testing, epitomised by breast cancer. Eur J Cancer. 1999;35:1954–1962
  2. Malkin D, Li FP, Strong LC, Fraumeni JF. Germ line p53 mutations in a familial sindrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238
  3. Sakorafas GH, Tsiotou AG. Genetic predisposition to breast cancer: a surgical perspective. Br J Surg. 2000;87:149–162
  4. Lu Y-J, Condie A, Bennett JD. Disruption of the ATM gene in breast cancer. Cancer Gen and Cytogen. 2001;126:97–101
  5. Kato N, Kimura K, Sugawara H. Germline mutation of the PTEN gene in a Japanese patient with Cowden's disease. Intern J Oncol. 2001;18:1017–1022
  6. Fackenthal JD, Marsh DJ, Richardson A-L. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38:159–164
  7. Buchholz TA, Weil MM, Story MD. Tumor suppressor genes and breast cancer. Radiat Oncol Invest. 1999;7:55–65
  8. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA-1 mutation carriers. Am J Hum Genet. 1995;56:265–271
  9. Breast Cancer Information Core (BIC) Database on the World Wide Web AT, http:www.nhgri.nih.gov/intramural research/lab transfer/bic
  10. Malone KE, Daling JR, Neal C. Frequency of BRCA1-BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88:1393–1402
  11. Peto J, Collins N, Barfoot R. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91:943–949
  12. Malone KE, Daling JR, Tomphson JD. BRCA1 mutations and breast cancer in the general population: analysis in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998;279:922–929
  13. Verhoog LC, Brekelmans C TM, Seyenaeve C. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000;83:384–386
  14. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA-1 and BRCA-2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–689
  15. Amos CL, Shaw GL, Tucher MA. Age at onset for familial epithelial ovarian cancer. JAMA. 1992;268:1896–1899
  16. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol. 2000;18:107S–112s
  17. Verhoog LC, Berns EMJJ, Berekelmans C TM. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol. 2000;18:119S–124s
  18. Narod SA, Brunet J-S, Ghadirian P. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876–1881
  19. Albano WA, Recabaren JA, Lynch HT. Natural history of hereditary cancer of the breast and colon. Cancer. 1982;50:360–363
  20. Robson M, Gilewski T, Haas B. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16:1642–1649
  21. Verhoog LC, Brekelmans C TM, Seynaeve C. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999;11:3396–3402
  22. Frank TS, Manley SA, Olopade OI. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417–2425
  23. Marcus JN, Watson P, Page D. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77:697–709
  24. Eisinger F, Stoppa-Lyonnet D, Longy M. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996;56:471–474
  25. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet. 1995;345:1503
  26. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fantiman IS. Histopathology of breast cancer in relation to age. Br J Cancer. 1997;75:593–596
  27. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, BRCA1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 1997;11:1226–1241
  28. Johannsson OT, Idvall I, Anderson C. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33:362–371
  29. Armes JE, Egan A JM, Southey MC. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998;83:2335–2345
  30. Armes JE, Trute L, White D. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers. a population-based study. Cancer Res. 1999;59:2011–2017
  31. Lynch BJ, Holden JA, Buys SS. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol. 1998;29:1140–1144
  32. Eisenger F, Jacquemier J, Charpin C. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 1998;58:1588–1592
  33. Eisenger F, Nogues C, Guinebretière J-M. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer. 1999;84:263–267
  34. Crook T, Brooks LA, Crossland S. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumors. Oncogene. 1998;17:1681–1689
  35. Noguchi S, Kasugai T, Miki Y. Clinicopathologic analysis of BRCA1- or BRCA2- associated hereditary breast carcinoma in Japanese women. Cancer. 1999;85:2200–2205
  36. Phillips KA, Nichol K, Ozcelik H. Frequency of p53 mutations in breast carcinomas of Ashkenazi Jewish BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:469–473
  37. Révillion F, Bonneterre J, Peyrat JP. ErbB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791–808
  38. Burstein HJ, Kuter I, Campos SM. Clinical activity of Trastuzumab and Vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19:2722–2730
  39. Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177–182
  40. Loman N, Johannsson O, Bendahl P-O. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998;83:310–319
  41. Agnarsson BA, Jonasson JG, Bjornsdottir IB. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat. 1998;47:121–127
  42. Salazar H, Godwin AK, Daly MB. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 1996;88:1810
  43. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia?. The Lancet. July 17, 1971;2:63
  44. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv. 1972;27:751–768
  45. Narod S, Goldgar D, Cannon-Albright L. Risk modifiers in carriers of BRCA-1 mutations. Int J Cancer (Pred Oncol). 1995;64:394–398
  46. Kerber RA, Slattery ML. The impact of history on ovarian cancer risk: the Utah population database. Arch Intern Med. 1995;155:905–912
  47. Karp SE, Tonin PN, Bégin LR. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80:435–441
  48. Foulkes WD, Wong N, Brunet JS. Germ-Line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997;3:2465–2469
  49. Ansquer Y, Gautier C, Fourquet A. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie breast cancer group. Lancet. 1998;352:541
  50. Lakhani SR, Jacquemier J, Sloane JP. Multifactorial analysis of differences between sporadic breast cancer and cancers involving BRCA1 and BRCA2 mutations. J Natl Canc Inst. 1998;90:1138–1145
  51. Verhoog LC, Brekelmans C TM, Seynaeve C. Survival and tumour characteristics of breast-cancer patients with germline mutation of BRCA1. Lancet. 1998;351:316–321
  52. Gretersdttir S, Thorlacius S, Valgardsdottir R. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Canc Res. 1998;58:859–862
  53. Lee JS, Wacholder S, Struewing JP. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:259–263
  54. Porter DE, Cohen BB, Wallace MR. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg. 1994;81:1512–1515
  55. Gaffney DK, Brohet RM, Lewis CM. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol. 1998;47:129–136
  56. Rubin SC, Benjamin I, Behbakht K. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996;335:1413–1416
  57. Buller RE, Anderson B, Connor JP, Robinson R. Familial ovarian cancer. Gynecol Oncol. 1993;51:160–166
  58. Boyd J, Sonoda Y, Federici MG. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260–2265
  59. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. J Clin Oncol. 1999;17:3653–3663
  60. Sigurdsson H, Agnarsson BA, Jonasson JG. Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene. Breast Cancer Res Treat. 1996;367:33
  61. Foulkes WD, Wong N, Rozen F, Brunet J-S, Narod SA. Survival of patients with breast cancer and BRCA1 mutations. Lancet. 1998;351:1359
  62. Pierce L, Strawderman M, Narod S. No deleterious effects of radiotherapy in women who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast-conserving therapy. Proc ASCO. 1999;18:86a
  63. Hamann U, Sinn H-P. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Canc Res Treat. 2000;59:185–192
  64. Offit K. Genetic prognostic markers for colorectal cancer. N Engl J Med. 2000;342:124–125
  65. Sankila R, Aaltonen LA, Jarvinen HJ, Meklin J-P. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682–687
  66. Struewing JP, Brody LC, Erdos MR. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet. 1995;57:1–7
  67. Ford D, Easton DF, Bishop DT. Risks of cancer in BRCA-1 mutation carriers. Lancet. 1994;343:692–695
  68. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318–2324
  69. Struewing JP, Hartge P, Wacholder S. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–1408
  70. Gayther SA, Mangion J, Russell P. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genetics. 1997;15:103–105
  71. Brunet J-S, Ghadirian P, Rebbeck TR. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998;90:761–766
  72. Narod SA, Risch H, Moslehi R. Oral contraceptives and the risk of hereditary ovarian cancer. N Eng J Med. 1998;339:424–428
  73. De Palo G, Veronesi U, Camerini T. Can Fenretinide protect women against ovarian cancer?. J Natl Cancer Inst. 1995;87:146–147
  74. Tobacman JK, Greene MH, Tucker MA. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;11:795–797
  75. Murday V. Genetic counselling in the cancer family clinic. Eur J Cancer. 1994;30A:2012–2015
  76. Weitzel JN. Genetic counselling for familial cancer risk. Hospital Practice. February 15, 1996;31:57–69
  77. Peshkin BN, DeMarco TA, Brogan BM. BRCA1/2 Testing: complex themes in result interpretation. J Clin Oncol. 2001;19:2555–2565
  78. Burke W, Daly M, Garber J. Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II BRCA1 and BRCA2. JAMA. 1997;277:997–1003
  79. Karlan BY, Platt LD. Ovarian cancer screening: the role of ultrasound in early detection. Cancer. 1995;76:2011–2015
  80. Woolas RP, Xu FJ, Jacobs IJ. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85:1748–1751
  81. Evron E, Dooley WC, Umbricht CB. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 2001;357:1335–1336
  82. Dooley WC, Veronesi U, Elledge R. Detection of premalignant and malignant breast cells by ductal lavage. Obst Gyn. 2001;97:S2
  83. Kaiser WA. False-positive results in dynamic MR mammography. MRI Clinics of North America. 1994;2:539–555
  84. Kumar NA, Schnall MD. MR imaging: its current and potential utility in the diagnosis and management of breast cancer. MRI Clinics of North America. 2000;8:715–728
  85. Bast RC, Ravdin P, Hayes DF. for the American society of clinical oncology tumor markers expert panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol. 2001;19:1865–1878
  86. Hankinson SE, Willett WC, Colditz GA. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 1998;351:1393–1396

PII: S0305-7372(01)90233-6

doi: 10.1053/ctrv.2001.0233

Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 295-304 , October 2001

Article Tools